Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
BIOCHEMICAL MODULATION OF FLUOROURACIL - COMPARISON OF METHOTREXATE, FOLINIC ACID, AND FLUOROURACIL VERSUS FOLINIC ACID AND FLUOROURACIL INADVANCED COLORECTAL-CANCER - A RANDOMIZED TRIAL
Autore:
POLYZOS A; TSAVARIS N; GIANNOPOULOS A; BACOYIANNIS C; PAPADIMAS V; KALAHANIS N; KARATZAS G; KOSMAS C; SAKELAROPOULOS N; ARCHIMANDRITIS A; PAPACHRISTODOULOU A; KOSMIDIS P;
Indirizzi:
UNIV ATHENS,SCH MED,LAIKO HOSP,DEPT PATHOPHYSIOL GR-11527 ATHENS GREECE UNIV ATHENS,SCH MED,LAIKO HOSP,DEPT PATHOPHYSIOL GR-11527 ATHENS GREECE UNIV ATHENS,SCH MED,LAIKO HOSP,DEPT PROPEDEUT MED 1 ATHENS GREECE
Titolo Testata:
Cancer chemotherapy and pharmacology
fascicolo: 3, volume: 38, anno: 1996,
pagine: 292 - 297
SICI:
0344-5704(1996)38:3<292:BMOF-C>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEQUENTIAL METHOTREXATE; 5-FLUOROURACIL; CARCINOMA;
Keywords:
BIOCHEMICAL MODULATION; 5-FLUOROURACIL; METHOTREXATE; FOLINIC ACID; ADVANCED COLORECTAL CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
A. Polyzos et al., "BIOCHEMICAL MODULATION OF FLUOROURACIL - COMPARISON OF METHOTREXATE, FOLINIC ACID, AND FLUOROURACIL VERSUS FOLINIC ACID AND FLUOROURACIL INADVANCED COLORECTAL-CANCER - A RANDOMIZED TRIAL", Cancer chemotherapy and pharmacology, 38(3), 1996, pp. 292-297

Abstract

Recant advances in biochemical pharmacology have revealed the basis for the biological modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and folinic acid (FA). Sequential use of MTX given 24 h prior to5-FU has resulted in enhanced cell kill in vitro and in vivo. In addition, administration of FA prior to 5-FU has led to potentiation of 5-FU action by stabilization of the ternary complex of thymidine synthase. In the present randomized study, two groups of patients with advanced colorectal cancer were treated as follows: 43 patients (pls) in group A received 5-FU + FA, whereas 45 pts in group B received 5-FU + FA MTX. The dosage-sas as follows: group A received FA i.v. at 300 mg/m(2) per day, prior to i.v. 5-FU at 500 mg/m(2) per day on days 1-4; group B was given MTX i.v. at 130 mg/m(2) per day on day 0, followed 24 h later by FA at 15 mg q6h x 6, and 5-FU + FA was started on day 1 andgiven at the same doses and schedule described for group A. Objectiveresponses were achieved by 8/43 pts in group A (1 complete response and 7 partial responses) and by 18/45 pts in group B (3 complete and 15partial responses), all occurring in the liver. There was no significant difference in the median time to progression (group A 6.1 months, group B 6.8 months) or the median survival (group A 9.2 months, group B 10.3 months). Toxicity was significantly greater in group B [grade 2-3 mucositis 20% versus only 2% in group A (P < 0.0001; grade diarrheain group B 15% versus 3% in group A (P < 0.001)]. According to our results, double biological modulation of 5-FU with MTX + FA led to an enhanced response rate with increased toxicity as compared with the 5-FU+ FA regimen given at less than its maximally tolerated dose.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 22:31:05